RISK WATCHYahoo Finance • 13h ago
Fractyl Health (GUTS) Stock Sees Fair Value Cut After Mixed Revita Analyst ReactionsYahoo Finance report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
Why GUTS Stock slipped -1.51% Today — RQD Quant Desk Flash
$0.98 -1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.98
Fractyl Health Inc. (GUTS) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $13.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GUTS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GUTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Fractyl Health Inc. (NASDAQ: GUTS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.98 (-1.51% 1D, market cap $13.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GUTS ranks #723 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GUTS compare to CNSY and SINT in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), GUTS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and SINT (SiNtx Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, GUTS leads on earnings multiple (N/A) while GUTS leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GUTS?
▼
Per GUTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001572616), Fractyl Health Inc. generated $0 in revenue (-100.0% YoY), -$141.0M in net income, and -$90.9M in free cash flow against $121.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.98 (-0.46%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GUTS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY GUTS SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.41-68.7% Next Q
42
Q2 (-2Q)Grade E$1.38-22.5% Next Q
39
Q3 (-1Q)Grade E$1.07-8.4% Next Q
37
CurrentGrade E$0.98-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GUTS Turnaround Squeeze
While GUTS currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.29) and Max Pain ($1.03) forces dealer call-delta covering toward $30.81.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GUTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GUTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GUTS Stock slipped -1.51% Today — RQD Quant Desk Flash
Fractyl Health Inc. (GUTS) slipped -1.51% to $0.98, trading at 2% of its 52-week range ($0.82 – $29.34). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.82 – $29.34) with RSI-14 at 17.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GUTS Headlines & Catalysts
RISK WATCHBenzinga • 16h ago
Why Fractyl Health Stock Is Sinking FridayBenzinga report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com • 19h ago
Canaccord cuts Fractyl Health stock price target on capital needsInvesting.com report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 22h ago
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance - Slideshow (NASDAQ:GUTS) 2026-10-16Seeking Alpha report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Why Fractyl Health (NASDAQ: GUTS) Stock Plunged 63% Despite Meeting Its REMAIN-1 Primary Endpointkalkine.ca report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETimothy Sykes • 1d ago
Fractyl Health Stock Collapses As GUTS Faces Class Action Over Revita DataTimothy Sykes report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
After stopping weight-loss drugs, people given a procedure kept about 80% of lost weightStock Titan report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Catalio Capital Management Trims Fractyl Health (GUTS) Stake by 88% in Major Portfolio AdjustmentGuruFocus report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential CommercializationPatent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenanceNew catheter patent provides protection extending t
RISK WATCHBenzinga • 3d ago
Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo SubmissionFractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GUTS)
- ✓Walkthrough of GUTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GUTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.76%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.89H $0.99L $0.89C $0.98VOL 710.9K
RES: $5.55SUP: $0.61SMA50: $5.29SMA200: $7.76
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GUTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GUTS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GUTS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GUTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GUTS)
Health Care Rank #723 of 1016
⚔️ CNSY vs GUTS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GUTS vs. CNSY, SINT, CTSO, ICU)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Fractyl Health Inc. (GUTS) ranks #723 by composite RQD confidence (34/100, grade E) and #869 by equity capitalization ($13.2M). Within this direct 5-issuer industry benchmark cohort, GUTS leads on earnings valuation at N/A trailing P/E, while GUTS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GUTS currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GUTS
ACTIVE
Fractyl Health Inc. | E | 34/100 | — | — | -35.0% | -1.51% | $13.2M | Benchmark Subject |
| CNSY Cerenome Inc. | E | 27/100 | — | — | -35.0% | -2.30% | $13.2M | /cnsy-vs-guts → |
| SINT SiNtx Technologies Inc. | E | 33/100 | — | 45.3% | -35.0% | -1.16% | $13.0M | /sint-vs-guts → |
| CTSO Cytosorbents Corporation | E | 22/100 | — | 71.5% | -35.0% | +3.18% | $13.9M | /ctso-vs-guts → |
| ICU SeaStar Medical Holding Corporation | E | 31/100 | — | 95.7% | -35.0% | -3.03% | $12.2M | /icu-vs-guts → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001572616In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fractyl Health Inc. (GUTS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $93.0K ) , GAAP net income of -$141.0M, operating cash flow of -$90.3M, and free cash flow of -$90.9M (-35.1% YoY). On the balance sheet, GUTS closed FY2025 with $121.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$141.0M | -$90.3M | -$90.9M | $121.4M | — |
| FY2024 (FY) | 2024-12-31 | $93.0K | -$68.7M | -$65.5M | -$67.3M | $108.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$77.1M | -$42.8M | -$42.8M | — | — |
3. GUTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GUTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Fractyl Health Inc. (NASDAQ: GUTS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.98 (-1.51% 1D, market cap $13.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GUTS ranks #723 in composite RQD confidence.
How does GUTS compare to CNSY and SINT in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), GUTS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and SINT (SiNtx Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, GUTS leads on earnings multiple (N/A) while GUTS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GUTS?
Per GUTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001572616), Fractyl Health Inc. generated $0 in revenue (-100.0% YoY), -$141.0M in net income, and -$90.9M in free cash flow against $121.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GUTS trading relative to its 50-day, 200-day, and 52-week technical levels?
GUTS last traded at $0.98 (-1.51% on volume of 387,020 shares), positioning the stock -81.47% below its 50-day simple moving average ($5.29) and -87.37% below its 200-day simple moving average ($7.76). Across its 52-week range of $0.82 to $29.34, GUTS sits at the 0.6% percentile with a 14-day RSI of 17.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).
GUTS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GUTS stock moving today?
Why GUTS Stock slipped -1.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
GUTS — Fractyl Health Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:02Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, GUTS scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 8 of 20, reflecting ROIC of -35% and an FCF yield of 0%. The Whale 13F Flow pillar scores 3 of 20 for institutional accumulation and options positioning. Insider Conviction scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 8 of 20, with a Beta of 1.0 and sector sensitivity noted. The Forensic Balance Sheet pillar scores 10 of 20, driven by an Altman Z-Score of 2.5, a Piotroski F-Score of 2 of 9, and a Debt/Equity ratio of 0.5.
For a prospective investor evaluating the stock today, the rating points to a company that is not currently generating cash from operations; the SEC financials show negative free cash flow in each reported year. The weakest pillars (whale flow and insider conviction) indicate limited sponsorship signals in the source data. The stronger forensic pillar reflects a balance sheet that the rating model considers less stressed than the cash engine, but the Piotroski score of 2 of 9 signals weak fundamental quality. Any upside thesis would depend on developments not captured in these metrics, and the rating itself is framed as a risk-avoidance signal.
Business
Fractyl Health Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the company profile, its market capitalization is $0.0B on a rounded basis, while the market data section lists $13.2M. The source data does not describe specific products, customers, or revenue model. Reported revenue across FY 2023 through FY 2025 is effectively zero ($0.0M to $0.1M), per the SEC financials.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-96.8M | $-141.0M | N/A | $-90.9M | $81.5M | N/A |
| FY 2024 | $0.1M | $-93.5M | $-68.7M | N/A | $-67.3M | $67.5M | N/A |
| FY 2023 | $0.0M | $-50.8M | $-77.1M | N/A | $-42.8M | N/A | N/A |
Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2 of 9. The Debt/Equity ratio is 0.5 per the rating inputs. Reported cash rose from $67.5M in FY 2024 to $81.5M in FY 2025 while free cash flow remained negative in every period shown.
Recent Catalysts & News Wire Analysis
- Analyst target cut (RED / RISK WATCH): A report indicates a fair value cut following mixed Revita analyst reactions.
- Price decline (RED / RISK WATCH): A Benzinga report covers the stock falling on a Friday, with the reason described in the headline.
- Price target reduction (RED / RISK WATCH): An Investing.com report states Canaccord cut its price target on capital needs.
- Positive trial readout (YELLOW / MARKET WIRE): A Seeking Alpha report discusses positive top-line 6-month results from the REMAIN-1 study of Revita in post-GLP-1 weight maintenance.
- Trial endpoint with share decline (YELLOW / MARKET WIRE): A kalkine.ca report describes a 63% share price drop despite the REMAIN-1 primary endpoint being met.
- Litigation (YELLOW / MARKET WIRE): A Timothy Sykes report describes a class action tied to Revita data.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no upstream or downstream dependencies and no sector correlations recorded. The source data therefore does not establish 2nd-order bottlenecks. The news wire does reference clinical data and litigation related to Revita, which a prospective investor may view as the primary channel through which regulatory or trial outcomes could ripple into the company's valuation, but the source data does not quantify such effects.
Open Questions
- What specific product or product pipeline generates revenue, given reported revenue of $0.0M to $0.1M across the periods shown?
- What is the debt position, given the financials list debt as N/A for every period?
- What are the capital needs referenced in the Canaccord price target cut, and how would they be funded?
- What is the outcome and scope of the class action referenced in the news wire?
- Why do EPS and several valuation multiples remain unavailable despite reported net losses?
GUTS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Fractyl Health Inc. (GUTS) • Click "Debate This Headline" to argue it in the Roar Pit below
🔴 RISK WATCH Yahoo Finance • 13h ago
Fractyl Health (GUTS) Stock Sees Fair Value Cut After Mixed Revita Analyst Reactions Yahoo Finance report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 16h ago
Why Fractyl Health Stock Is Sinking Friday Benzinga report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com • 19h ago
Canaccord cuts Fractyl Health stock price target on capital needs Investing.com report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 22h ago
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance - Slideshow (NASDAQ:GUTS) 2026-10-16 Seeking Alpha report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Why Fractyl Health (NASDAQ: GUTS) Stock Plunged 63% Despite Meeting Its REMAIN-1 Primary Endpoint kalkine.ca report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Timothy Sykes • 1d ago
Fractyl Health Stock Collapses As GUTS Faces Class Action Over Revita Data Timothy Sykes report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
After stopping weight-loss drugs, people given a procedure kept about 80% of lost weight Stock Titan report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Catalio Capital Management Trims Fractyl Health (GUTS) Stake by 88% in Major Portfolio Adjustment GuruFocus report covering Fractyl Health Inc. (GUTS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GUTS Bull vs. Bear Conversation Board — What's Your Call at $0.98?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GUTS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.87 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is GUTS (E • RQD 34/100) a Buy at $0.99?
Welcome to the GUTS (Fractyl Health Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.75 (-24.2%)
Spot @ $0.99 Pump the brakes on GUTS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GUTS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Fractyl Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.21 (+22.2%)
Spot @ $0.99 GUTS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GUTS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.99 (52-wk range $0.82 - $29.34), any beat on forward guidance forces shorts and underweight funds to chase.